Pipeline

Our pipeline features nine therapeutics to treat Alzheimer’s disease and offers unprecedented benefits:

     1. Definitive targets – antigens that cause Alzheimer’s

                      2. Definitive biomarkers – measure the antigens of Alzheimer’s

3. Inherently optimized- to guide the clinical trials

Aven's Pipeline

Therapeutic Collaborations

Faster, More Efficient, More Successful Drug Development

  • New drug developers can isolate definitive therapeutic targets and map epitope-gene-ID for precise immunotherapies.
  • Existing drug developers can now measure specific antibodies at every stage of the disease and monitor longitudinal trends during treatments.

For Clinical Trials

For Drug Development


For Clinical Trials

Recruitment
Acuurately identify responsive subjects

Recruitment

Retrospective
Retrospectively stratify subjects of past clinical trials

Retrospective

Longitudinal
Longitudinally monitor subject’s drug response during clinical trials to develop Companion diagnostics

Longitudinal

Prospective
Prospectively recruitment subjects for future clinical trials

Prospective


For Drug Discovery

Target Isolation

Definitively identify disease-causing pathogenic antigens.

Target Isolation

Immunotherapy

“Epitope-Gene ID” mapping to link immunotherapeutics.

“Epitope-Gene ID” mapping to link immuno-therapeutics

 
For partnering inquiries, please contact: partnering@anvenbio.com